- Home
- BAP vs BMRN Comparison
BAP vs BMRN Comparison
Compare BAP & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAP
- BMRN
- Stock Information
- Founded
- BAP 1889
- BMRN 1996
- Country
- BAP Peru
- BMRN United States
- Employees
- BAP N/A
- BMRN N/A
- Industry
- BAP Major Banks
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- BAP Finance
- BMRN Health Care
- Exchange
- BAP Nasdaq
- BMRN Nasdaq
- Market Cap
- BAP 14.5B
- BMRN 12.1B
- IPO Year
- BAP 1995
- BMRN 1999
- Fundamental
- Price
- BAP $203.94
- BMRN $59.82
- Analyst Decision
- BAP Hold
- BMRN Buy
- Analyst Count
- BAP 3
- BMRN 22
- Target Price
- BAP $195.67
- BMRN $93.43
- AVG Volume (30 Days)
- BAP 244.3K
- BMRN 1.6M
- Earning Date
- BAP 05-15-2025
- BMRN 05-01-2025
- Dividend Yield
- BAP 6.77%
- BMRN N/A
- EPS Growth
- BAP 13.11
- BMRN 152.82
- EPS
- BAP 18.32
- BMRN 2.71
- Revenue
- BAP $4,825,226,157.00
- BMRN $2,950,227,000.00
- Revenue This Year
- BAP $25.86
- BMRN $12.27
- Revenue Next Year
- BAP $6.09
- BMRN $9.86
- P/E Ratio
- BAP $10.93
- BMRN $22.11
- Revenue Growth
- BAP 12.46
- BMRN 19.36
- 52 Week Low
- BAP $153.27
- BMRN $52.93
- 52 Week High
- BAP $205.02
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- BAP 64.99
- BMRN 40.34
- Support Level
- BAP $198.73
- BMRN $60.92
- Resistance Level
- BAP $203.09
- BMRN $65.40
- Average True Range (ATR)
- BAP 4.34
- BMRN 1.96
- MACD
- BAP 0.91
- BMRN 0.06
- Stochastic Oscillator
- BAP 94.98
- BMRN 21.52
About BAP Credicorp Ltd.
Credicorp Ltd is a Peruvian financial services company. It operates in four business lines including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.